Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TRPM4 | Q8TD43 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26669028 | 0.88 | TDP1 (0.49) | TDP1TRPM4TSHRSMN1; SMN2CASP1 | |
| SCHEMBL4134095 | 0.84 | TDP1 (0.65) | TDP1TSHRSMN1; SMN2CASP1AKR1B1 | |
| SCHEMBL1546386 | 0.81 | TSHR (0.52) | TSHRSMN1; SMN2CASP1GAAMAPT | |
| SCHEMBL28948098 | 0.81 | TSHR (0.54) | TDP1TRPM4TSHRSMN1; SMN2CASP1 | |
| SCHEMBL4675125 | 0.81 | POLB (0.52) | TDP1TRPM4TSHRSMN1; SMN2CASP1 | |
| SCHEMBL9187673 | 0.80 | TSHR (0.50) | TSHRSMN1; SMN2CASP1GAAMAPT | |
| SCHEMBL13607848 | 0.78 | DHODH (0.53) | TDP1TSHRSMN1; SMN2CASP1GAA | |
| SCHEMBL19859014 | 0.77 | TSHR (0.47) | TSHRSMN1; SMN2CASP1GAAMAPT | |
| SCHEMBL13951660 | 0.76 | TSHR (0.50) | TRPM4TSHRSMN1; SMN2CASP1GAA | |
| SCHEMBL4302213 | 0.76 | KDM4E (0.50) | TDP1TRPM4TSHRSMN1; SMN2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681207-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2681207-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | Bioenergenix (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012119046-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | TDP1 2483/4885TRPM4 3106/4885TSHR 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.